Treatment and outcomes of patients with HR+/HER2− early breast cancer in a real-world setting in Germany

A considerable subset of patients with HR+/HER2- EBC present with high-risk clinicopathological characteristics, which indicate a negative impact on prognosis, thus highlighting the need for novel treatment strategies for this patient population.